Connor, Clark & Lunn Investment Management Ltd. Bellus Health Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$7.14 - $8.53 $2.63 Million - $3.14 Million	-368,300 Reduced 33.29%	738,200 $5.32 Million
Q4 2022 Feb 10, 2023	BUY	$8.22 - $10.76 $3,288 - $4,304	400 Added 0.04%	1,106,500 $9.1 Million
Q3 2022 Nov 10, 2022	BUY	$8.95 - $12.0 $1.98 Million - $2.65 Million	220,970 Added 24.96%	1,106,100 $11.7 Million
Q2 2022 Aug 05, 2022	BUY	$6.46 - $10.02 $503,427 - $780,858	77,930 Added 9.65%	885,130 $8.15 Million
Q1 2022 May 12, 2022	BUY	$5.56 - $7.99 $3.45 Million - $4.96 Million	621,300 Added 334.21%	807,200 $5.58 Million
Q4 2021 Feb 10, 2022	BUY	$5.26 - $8.3 $977,834 - $1.54 Million	185,900 New	185,900 $1.5 Million

Others Institutions Holding BLU

# of Institutions

Shares Held

128K

Call Options Held

Put Options Held

Pendal Group LTD

128K
Shares

$0
0.01% of portfolio

View Full List

About BELLUS Health Inc.

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

More about BLU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account